Trial · NCT00380068
Outcomes17
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline to Week 24 in 6 Minute Walk Distance (6MWD) | Baseline to Week 24 | Full Analysis Set. Last Observation Carried forward. 4 participants were excluded from the analysis due to lack of post-baseline 6MWD data. | meters | MEAN |
| SECONDARY | Change From Baseline to Week 24 in Borg Dyspnea Index | Baseline to Week 24 | Full Analysis Set. Last Observation Carried forward. 4 participants were excluded from the analysis due to lack of post-baseline Borg Dyspnea Index data. | Units on a scale | MEAN |
| SECONDARY | Change From Baseline to Week 48 in Borg Dyspnea Index | Baseline to Week 48 | Full Analysis Set. Observed data. 114 participants were excluded from the analysis due to lack of Week 48 Borg Dyspnea Index data. | Units on a scale | MEAN |
| SECONDARY | Percent Change From Baseline to Week 24 in B-type Natriuretic Peptide (BNP) | Baseline to Week 24 | Full Analysis Set. Last Observation Carried forward. 10 participants were excluded from the analysis due to lack of baseline or post-baseline BNP data. | Percent change in BNP | GEOMETRIC_MEAN |
| SECONDARY | Percent Change From Baseline to Week 48 in BNP | Baseline to Week 48 | Full Analysis Set. Observed data. 111 participants were excluded from the analysis due to lack of baseline or Week 48 BNP data. | Percent change in BNP | GEOMETRIC_MEAN |
| SECONDARY | Change From Baseline to Week 24 in WHO Functional Class | Baseline to Week 24 | Full Analysis Set. Last Observation Carried Forward. 3 participants were not analyzed due to lack of post-baseline WHO functional class data. | Percentage of participants | NUMBER |
| SECONDARY | Change From Baseline to Week 48 in WHO Functional Class | Baseline to Week 48 | Full Analysis Set. Observed Data. 3 participants were not analyzed due to lack of post-baseline WHO functional class data. | Percentage of participants | NUMBER |
| SECONDARY | Change From Baseline to Week 24 in SF-36 Health Survey Physical Functioning Scale | Baseline to Week 24 | Full Analysis Set. Last Observation Carried forward. 26 participants were excluded from the analysis due to lack of baseline or post-baseline SF-36 data. | Units on a scale | MEAN |
| SECONDARY | Change From Baseline to Week 48 in SF-36 Health Survey Physical Functioning Scale | Baseline to Week 48 | Full Analysis Set. Last Observation Carried forward. 25 participants were excluded from the analysis due to lack of baseline or post-baseline SF-36 data. | Units on a scale | MEAN |
| SECONDARY | Percent of Participants With no Clinical Worsening of Pulmonary Hypertension (PH) at Week 24 | Baseline to Week 24 | Full analysis set. Participants who were lost to follow-up were censored at the date of last contact. | Percentage of participants | NUMBER |
| SECONDARY | Percent of Participants With no Clinical Worsening of PH at Week 48 | Baseline to Week 48 | Full analysis set. Participants who were lost to follow-up were censored at the date of last contact. | Percentage of participants | NUMBER |
| SECONDARY | Failure-free Treatment Status | Baseline to Week 24 | Full Analysis Set. Participants who were lost to follow-up were censored at the date of last contact. | Percentage of participants | NUMBER |
| SECONDARY | Failure-free Treatment Status | Baseline to Week 48 | Full Analysis Set. Participants who were lost to follow-up were censored at the date of last contact. | Percentage of participants | NUMBER |
| SECONDARY | Monotherapy Treatment Status | Baseline to Week 24 | Full Analysis Set - Subset of participants who were not receiving other PH therapy at baseline. | Percentage of participants | NUMBER |
| SECONDARY | Monotherapy Treatment Status | Baseline to Week 48 | Full Analysis Set - Subset of participants who were not receiving other PH therapy at baseline. | Percentage of participants | NUMBER |
| SECONDARY | Long-term Survival | Baseline to Week 24 | Full Analysis Set. Participants who were lost to follow-up were censored at the date of last contact. | Percentage of participants | NUMBER |
| SECONDARY | Long-term Survival | Baseline to Week 48 | Full Analysis Set. Participants who were lost to follow-up were censored at the date of last contact. | Percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00380068/outcomes